A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4 by Cuzick, J et al.
A comparison of different human papillomavirus tests in PreservCyt
versus SurePath in a referral population-PREDICTORS 4.
Cuzick, J; Ahmad, AS; Austin, J; Cadman, L; Ho, L; Terry, G; Kleeman, M; Ashdown-Barr, L;
Lyons, D; Stoler, M; Szarewski, A
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14793
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
A Comparison of Different Human Papillomavirus tests in PreservCyt versus SurePath in a Referral 1 
Population – PREDICTORS 4 2 
Jack Cuzick1, Amar S. Ahmad1, Janet Austin1, Louise Cadman1, Linda Ho1, George Terry1, Michelle 3 
Kleeman1, Lesley Ashdown-Barr1, Deirdre Lyons2, Mark Stoler3, Anne Szarewski 1* 4 
1 - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University 5 
of London, Charterhouse Square, London, EC1M 6BQ, UK 6 
2 - Department of Colposcopy, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, 7 
W2 1NY, UK   8 
3 - Department of Pathology, University of Virginia Health System, Charlottesville, Virginia 22908, 9 
USA 10 
* Deceased 11 
Address for correspondence: 12 
Jack Cuzick, PhD  13 
Centre for Cancer Prevention  14 
Wolfson Institute of Preventive Medicine 15 
Queen Mary University of London 16 
Charterhouse Square, London, EC1M 6BQ, UK 17 
Phone: +44 20 7882 3504 18 
Fax: +44 20 7882 3890 19 
2 
 
Email: j.cuzick@qmul.ac.uk  20 
 21 
Running title: 22 
PreservCyt versus SurePath: PREDICTORS 4 23 
 24 
Key words: Human papillomavirus testing, cervical screening, PreservCyt, ThinPrep, SurePath.  25 
 26 
Highlights: 27 
 First comparison of HPV tests in PreservCyt and SurePath, 2 samples from each woman 28 
 Nucleic acid HPV tests showed similar performance in PreservCyt and SurePath 29 
 Manufacturers’ recommended pre-treatment protocols must be observed 30 
 31 
Word count: Abstract:  291 32 
  Main text:  2550 33 
Number of tables: 4 34 
Number of figures: 2 35 
Number of supplementary tables: 1 36 
Number of supplementary figures: 7  37 
 38 
3 
 
Abstract 39 
Background. Two transport media, PreservCyt and SurePath, are widely used for cervical cytology 40 
screening. There are concerns that they may perform differently for HPV testing. 41 
Objectives. A comparison of the performance of six different HPV tests in SurePath and PreservCyt 42 
in a referral population using two samples from each woman. The primary goal was to compare the 43 
performance of each test in the two media.  Comparisons between assays and viral load 44 
comparisons between media were secondary aims. 45 
Study design. Two cervical samples were collected in random order at the same visit in women with 46 
abnormal cytology. One sample was placed in 20ml of PreservCyt and the other in 10ml of SurePath. 47 
Aliquots were taken for 4 DNA based tests: digene HC2 High-Risk HPV DNA Test, Abbott Realtime, BD 48 
Onclarity  and Genera PapType, an RNA based test - Hologic Aptima and a protein test: Oncohealth.  49 
Results. 630 sample pairs were included in the analyses. For all tests except the protein test 50 
sensitivities were in excess of 90% for CIN2+ and 95% for CIN3+ for both media and with no 51 
significant differences except for a lower sensitivity for CIN2+ of Aptima in SurePath ( 93% vs 98%, P 52 
= 0.005). Specificity for <CIN2 was significantly better in Surepath for HC2, RealTime and Aptima, and  53 
generally lower relative signal strengths were seen with SurePath except for Onclarity, especially 54 
when it was the second sample . 55 
Conclusions. We found similar sensitivity for CIN3+ in PreservCyt and SurePath for 5 nucleic acid 56 
tests in the two media in a referral population, but signal strength and positivity rates were lower in 57 
SurePath except for the Onclarity test. These results need to be replicated in a screening population. 58 
59 
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 60 
Background 61 
Two liquid-based cytology (LBC) systems are commonly used: ThinPrep using PreservCyt transport 62 
medium (Hologic Inc., Marlborough, MA) and SurePath (Becton Dickinson, Sparks, MD) using 63 
SurePath Preservative Fluid. Slide preparation procedures from these media are different1,2. Cells are 64 
normally collected using a Cervex-Brush (Rovers Medical Devices, Oss, Netherlands) but in 65 
PreservCyt cells are rinsed into the medium, dispersed by vortexing, and transferred to a microscope 66 
slide after vacuum filtration. In SurePath, the detached head of the brush is placed in the medium. 67 
After initial centrifugation cells are resuspended, put through a density gradient centrifugation with 68 
sampling of the pellet to make the slide. The performance of both systems for cytology is 69 
comparable1,3. 70 
 71 
An advantage of LBC is that additional tests, notably HPV, can be run from a single sample, although 72 
only PreservCyt is approved by the FDA for this. Unlike PreservCyt, SurePath contains formaldehyde 73 
to preserve cell morphology and cross-linkage between protein and nucleic acid can occur which can 74 
make DNA undetectable and reduce DNA yield. This is partially reversible using proteinase K (PK) 75 
digestion and/or heat treatment prior to nucleic acid purification4,5,6. It is currently unclear whether 76 
such treatment can provide sufficient native HPV DNA/RNA from individual cervical samples for 77 
different HPV assays.  78 
 79 
The majority of early studies of HPV testing in a medium also suitable for cytology have been 80 
conducted using Qiagen’s digene HC2 High-Risk HPV DNA Test (HC2) in PreservCyt. In a study of 972 81 
SurePath and 1033 PreservCyt screening samples in different women Zhao et al. (2011) found no 82 
significant difference in sensitivity and specificity for the detection of CIN2+ by HC27. A Danish study 83 
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of 5064 screening samples found the positivity rate correlated moderately well (kappa≥0.60) 84 
between four assays (HC2(Qiagen), Cobas(Roche), CLART(Genomica) and Aptima(Hologic)) using 85 
SurePath and multiple testing on one sample from each woman8. In another study of 367 women 86 
with abnormal cytology similar sensitivities were reported for these four assays9. The UK Sentinel 87 
Sites study of 10,051 women referred with borderline or mild dyskaryosis showed a higher overall 88 
HPV positivity rate in PreservCyt than SurePath (68.7% vs 61.7%, p<0.0001). However this may be 89 
confounded by site as all but one site used only one medium and the site using both media found no 90 
significant difference in positive rates10. To our knowledge, there has not been a comparison of the 91 
performance of different HPV assays using PreservCyt and SurePath samples collected from the 92 
same woman. 93 
 94 
Objective 95 
The objective of this study was a comparison of the performance of different HPV testing assays in 96 
SurePath and PreservCyt in a routine clinical setting. We used a colposcopy referral population and 97 
compared six HPV assays using two samples from each woman – one collected in PreservCyt and the 98 
other in SurePath. Our primary goal was to compare the performance of each test in the two media.  99 
Comparisons between assays were secondary aims. 100 
 101 
Study design 102 
The study was conducted in the Colposcopy Unit of St. Mary’s Hospital, London among women who 103 
had been referred with an abnormal screening result within three months and never treated for CIN. 104 
All women provided written informed consent. 105 
 106 
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Two cervical samples were collected with Cervex-Brushes immediately prior to colposcopic 107 
examination in accordance with European guidelines for quality assurance with cervical cancer 108 
screening11. To minimise bias, the order of use of transport medium was randomly assigned (1:1). 109 
One brush was agitated in a vial containing 20ml of PreservCyt. The other brush head was removed 110 
and deposited in a vial containing 10ml of SurePath. All samples were stored at 4°C and transferred 111 
within two weeks of collection to the laboratory at the Wolfson Institute of Preventive Medicine, 112 
where HPV testing was performed.  113 
 114 
Within one day of receipt in the laboratory, samples were warmed to room temperature, agitated 115 
for 60 seconds and aliquotted into a fixed order set of tubes, appropriate for six assays. This was 116 
pseudo-randomised to vary the aliquot assigned to each assay by using one of four dispensing 117 
patterns (left to right, right to left, centre to right then centre to left, centre to left then centre to 118 
right). Samples were only identifiable to laboratory staff by participant number. All pathology was 119 
reviewed by M.S. who was blinded to results and participant information. 120 
 121 
Laboratory Methods 122 
Sample storage before testing, aliquot volumes and positivity cut-off values were all in accordance 123 
with the manufacturers’ instructions (Table 1). No tests were done on post-gradient pellets. 124 
Manufacturers use ‘Invalid’ or ‘Indeterminate’ to denote failed results including when a whole plate 125 
or run fails. We refer to all as ‘Failed’ results in this paper. 126 
 127 
Assays 128 
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DNA based: 129 
 digene HC2 High-Risk HPV DNA Test: The QIAsymphony automated platform was used for 130 
nucleic acid extraction with the DSP AXpH DNA Kit (Qiagen, Hilden, Germany). This 131 
consensus DNA test detects a panel of 13 high-risk HPV types 132 
(16,18,31,33,35,39,45,51,52,56,58,59,68). PreservCyt and SurePath samples were processed 133 
using different protocols: PC_AXpH_hc2_V1_DSP protocol and a modified SP2000_V1_DSP 134 
protocol including PK digestion and extended heated lysis time (provided by Qiagen for 135 
research purposes only) respectively12. 4ml PreservCyt or 0.5ml of SurePath diluted in 2ml of 136 
deionised water were used. Resulting eluates (60μl) were dispensed into a 96 well 137 
microplate for manual testing. Signal strength was measured in Relative Light Units (RLU) 138 
compared to a reference of approximately 5000 HPV copies.  139 
  Abbott RealTime High-Risk HPV assay used the m2000 processing System (Abbott 140 
Molecular, Abbott Park, Illinois) for the detection of 14 high-risk HPV types, utilising Abbott 141 
reaction vessels as sample input tubes. Types 16 and 18 are individually reported. The 142 
remaining 12 high-risk types are reported together as a 143 
pool(31,33,35,39,45,51,52,56,58,59,66,68). 144 
 Becton Dickinson Onclarity HPV Assay using the BD Viper LT System is a real-time PCR based 145 
DNA test which detects 14 high-risk HPV types. Types 16,18,31,45,51,52 are detected 146 
individually. The remaining eight high-risk types are reported in three groups: (33,58), 147 
(35,39,68) and (56,59,66). A 0.5ml aliquot of thoroughly vortexed SurePath or PreservCyt 148 
was added to 1.7ml of a proprietary HPV diluent. A heat step was employed to ensure that 149 
exfoliated cells were lysed and the sample homogenized prior to extraction of sample 150 
DNA4,5. 151 
 Genera PapType Test is a semi-automated, bead-based multiplex full genotyping DNA assay 152 
for 14 high-risk HPV types (16,18,31,33,35,39,45, 51,52,56,58,59,66,68) and two low-risk 153 
HPV types (6,11). The Sirocco platform (Genera Biosystems, Scoresby, Australia) was used. 154 
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Prior nucleic acid extraction was done using the Abbott m2000sp instrument13. Only high-155 
risk types were considered positive in this study. The assay measure is derived from flow 156 
cytometry and reported as S (signal). Type specific cut-offs were used (Table 1). 157 
RNA based:  158 
 Hologic Aptima HPV assay is based on target capture, transcription-mediated amplification 159 
and hybridization protection for the detection of E6/E7mRNA expression of 14 high-risk HPV 160 
types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). A consensus result for positivity to other 161 
high-risk types was provided. The Direct Tube Sampling platform was used. Typing for 16 162 
and 18/45, available as a reflex test, was not done here. The SurePath sample was treated 163 
with PK at 65°C for 2 hours before being assayed manually. The cut-off was specified to be 164 
0.5 of the ratio of the intensity to the reference standard. 165 
 166 
Protein based assay: 167 
 OncoHealth (OncoHealth, San Jose, California) protein test is a direct E6/E7 HPV Whole-Cell 168 
ELISA carried out in microtitre wells and is based on detection by non-type specific HPV E6 169 
and E7 monoclonal antibodies14. Relative Optical Density (ROD) was used compared to a 170 
reference value of 0.35. 171 
 172 
For all HPV tests except HC2 both samples were processed using an identical assay workflow. Test 173 
details using Preservcyt for HC2, Onclarity, RealTime, PapType and Aptima have been described 174 
previously13,15,16,17. 175 
 176 
Statistical analysis 177 
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Primary analyses consisted of paired comparison of the two samples from each woman. For some 178 
assays confounding was observed related to the order in which the sample was taken. Subsequently 179 
additional non-paired analyses by the Wilcoxon Ranksum test and a robust L1 based linear model 180 
with allowance for test order were also conducted17. A measure of viral load (log(1+relative intensity 181 
units (RIU)) or minus Ct values) was used to perform correlation and regression analyses with 182 
adjustment for sample order for paired samples within each test. Here RIU refers to the signal 183 
strength of the sample compared to a standard (Table 1). Non-amplified samples for Onclarity and 184 
RealTime were given a Ct value of 40 and signal strength 0 for Aptima. SAS (version 9.2) and R 185 
(version 3.2.2) were used. All statistical tests were two-sided and a p-value of 0.05 accepted as 186 
statistically significant.  187 
Results 188 
The analysis was based on 630 sample pairs from 652 participating women. Reasons for drop out are 189 
shown in Figure 1. Median age was 30.0 years (IQR=[27.0,34.8]).  HC2 was introduced during the 190 
study, and only the last 344 sample pairs were tested.  There were no failed results for HC2, 191 
Onclarity, Oncohealth or RealTime. For PapType one sample pair was not tested with either medium 192 
and 46 tests failed (44 sample pairs; 16 in PreservCyt, 30 in SurePath). For Aptima there were 22 193 
failed tests (17 sample pairs; 10 in PreservCyt, 12 in SurePath). 194 
Entry cytology was borderline dyskaryosis 193(30.6%), mild dyskarosis 380(60.4%), moderate 195 
dyskaryosis 37(5.9%) and severe dyskaryosis or glandular abnormality 20(3.2%). A total of 196 
176(28.0%) histology results were CIN2 or worse, including 94(15.0%) cases of CIN3 or CGIN and 197 
2(0.3%) cases of invasive cancer. (Supplementary table S1). 198 
 199 
Overall positivity, sensitivity for CIN3+ and CIN2+ and specificity for<CIN2 for the different tests and 200 
transport media is shown in Table 2. Sensitivity and specificity for CIN2+ is further illustrated in 201 
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Figure 2 and CIN3+ in Supplementary Figure 1. All tests showed high sensitivities for both samples in 202 
excess of 90% for CIN2+ and 95% for CIN3+, except OncoHealth which had low sensitivity in both 203 
media.  A matched-pairs analysis indicated no significant difference between media for sensitivity for 204 
either CIN2+ or CIN3+ for any test, except for Aptima which was slightly less sensitive in SurePath 205 
(98% vs 93%,  P=0.005). However, there were differences in specificity with significantly higher 206 
specificities for HC2, RealTime, Aptima and OncoHealth in SurePath.  Although showing some 207 
predictive ability above chance in PreservCyt, the OncoHealth test was substantially and significantly 208 
less sensitive than all other tests (≤60% for both media for both CIN2+ and CIN3+), but was more 209 
specific than the other assays. There was no significant difference however with the OncoHealth 210 
assay between media. 211 
Signal strength (viral load estimate) differed by transport medium and test order (Table 3). Little 212 
difference was seen between the two media when used as a first test, except for substantially higher 213 
values for RealTime in SurePath (P<2x10-5) and HC2 in PreservCyt (P=0.009). For HC2 this probably 214 
reflects a larger sample volume for PreservCyt. Significantly higher values were seen for PreservCyt 215 
(vs SurePath) when both were used as a second sample especially for HC2, again with the exception 216 
of Onclarity. Type specific results for HPV16 and 18 for RealTime, Onclarity and PapType gave a 217 
similar pattern (Table 3).  218 
PreservCyt values were not statistically significantly different between the first versus second 219 
samples in all cases except for OncoHealth where they were substantially lower in the second 220 
sample (Table 3). For SurePath, significant differences between the first and second sample were 221 
seen for all tests, but the second sample gave higher levels for RealTime and Onclarity and lower 222 
levels for the other tests. For HC2 the RLU values were much lower in the second sample for 223 
SurePath, possibly due to the smaller sample volume.   224 
Correlation between signal strength measurements for the two media for each test is shown in Table 225 
4. While correlations for the tests in the two media were quite good, except for OncoHealth, the 226 
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slopes were significantly less than unity for all tests except HC2 which was 0.966 (p=0.23),indicating 227 
that the values are generally higher for PreservCyt. Minimal correlation between media could be 228 
seen for the OncoHealth test. A fuller presentation of the differences between the two media is 229 
shown as scatterplots for each test in Supplementary Figures S2-7, in which the order of the test is 230 
also depicted.  231 
 232 
Discussion 233 
Our results indicate that similar sensitivities and specificities can be achieved with either PreservCyt 234 
or SurePath for 5 of the 6 HPV tests, provided that the manufacturer’s recommended pre-235 
treatments are observed. Some loss of sensitivity for CIN2+ was seen for RealTime and Aptima in 236 
SurePath, but this was minimal for CIN3+. The largest differences were seen for specificity which was 237 
generally better for SurePath, especially for HC2, RealTime and Aptima. This is likely to also be true 238 
for primary screening but direct verification in this setting is needed. Poor performance was seen for 239 
the Oncohealth protein test in both media.  This protein-based test however is known to be less 240 
stable in alcohol and a second generation test has been developed since this study was carried out. 241 
The failure rate for PapType was relatively high (3.6%, 45/1260). No specific reason could be 242 
identified, but this was a prototype test with the complexity of full typing, so improvements are 243 
likely in the future. The failure rate was 1.3% for Aptima, but there were no failures for other tests. 244 
The differences between tests were greater for the second than the first sample, illustrating the 245 
differences in a true diagnostic situation where only a first sample would be used. This highlights the 246 
need for an adequate sample and may be a factor in the discordant results between assays as found 247 
by Rebolj et al (2014)8.The SurePath vial contained 10mls and PreservCyt 20mls of transport 248 
medium, thus concentration of cells in SurePath is greater than PreservCyt. The only test where the 249 
amount of DNA in the tested sample would be expected to be the same in both media would be the 250 
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Aptima test where the aliquot volume was 1ml of PreservCyt and 0.5ml of SurePath.  All others tests 251 
except HC2 used an equal aliquot volume (0.5ml) and would lead to less DNA in the PreservCyt 252 
sample. For HC2 4mls were assayed from PreservCyt versus 0.5ml from SurePath. However this had 253 
no measurable impact on the results.  254 
Although not of direct clinical relevance, comparison of the quantitative measures of signal strength 255 
as a surrogate measure of viral load provides additional insight into the comparative performance of 256 
the different tests in the two transport media. We recognise several confounding factors to this 257 
measure including cell number and specific methods of measuring signal strength. In general lower 258 
signal strength values were obtained for SurePath. The largest differences were seen for HC2 259 
potentially partly attributable to smaller sample volume for SurePath.  260 
Most HPV assays have been more fully optimized for PreservCyt, which has been in use for longer. 261 
An exception is the Onclarity assay, developed by the manufacturer of SurePath. The Onclarity assay 262 
uses a heat step in sample pre-processing for both sample types and little difference between media 263 
was seen. At the time of this study no HPV test manufacturer had an approved protocol for their 264 
assay in the SurePath medium and it is possible that this will impact on performance.  265 
In summary this prospective study is the first comprehensive comparison of a range of HPV tests in 266 
the two most commonly used LBC transport media, where two samples are taken from each woman. 267 
No major differences in performance were seen when the manufacturer’s protocols were used.  268 
These tests have all performed well in this referral population and although all appear suitable for 269 
screening they need to be validated in a screening population using Arbyn’s criteria11. 270 
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Table 1. HPV assays performed, positivity cut-off and aliquot volume. 344 
Test Positivity Cut-offa b Aliquot volume (ml) 
  PreservCyt SurePath 
HC2 ≥ 1 RLU 4.0 0.5 
RealTime  ≤ 32 Ct 0.5 0.5 
Onclarity  ≤ 34.2 Ct 0.5 0.5 
PapType  HPV58 ≥ 0.0004  
HPV68 ≥ 0.0003 
All others ≥ 0.0002  
0.5 0.5 
Aptima  ≥ 0.5 RIU 1.0 0.5 
OncoHealth  ≥ 0.35 OD 1.0 1.0 
a For all tests except RealTime and Onclarity, units are ratio of signal strength to reference standard 345 
b RLU – relative light units; Ct – cycle threshold; RIU – relative intensity units; OD –optical density 346 
347 
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 348 
349 
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Table 2. Overall positivity, sensitivity for CIN3+ and CIN2+, specificity for < CIN2 and agreement for 350 
different tests and transport media. 351 
 Overall             Sensitivity Specificity 
 
positivity  
(%) 
CIN3+ 
(N = 96) c 
CIN2+ 
(N = 176) c 
   <CIN2 
(N = 454) c 
HC2 (N = 344) 
PreservCyt 289 (84) 0.98 0.97 0.21 
SurePath 269 (78) 0.98 0.96 0.28 
     
Agreement (%) 89.5 95.6 94.5 87.7 
Discordanta 28 vs 8 1 vs 1 3 vs 2 25 vs 6 
P-value b 0.001 1 1 0.001 
RealTime (N = 630) 
PreservCyt 476 (76) 0.99 0.95 0.32 
SurePath 447 (71) 0.97 0.91 0.37 
     
Agreement (%) 93.8 95.8 94.3 93.6 
Discordanta 34 vs 5 3 vs 1 8 vs 2 26 vs 3 
P-value b 2.4 x 10-6 0.62 0.11 1.5 x 10-5 
Onclarity (N = 630) 
PreservCyt 486 (77) 1.00 0.97 0.31 
SurePath 494 (78) 1.00 0.97 0.29 
     
Agreement (%) 97.1 100 100 96 
Discordant a 5 vs 13 0 vs 0 0 vs 0 5 vs 13 
P-value b 0.10 1 1 0.10 
PapType ( N= 585) 
PreservCyt 465 (79) 0.96 0.93 0.26 
19 
 
SurePath 469 (80) 0.96 0.94 0.25 
     
Agreement (%) 93.5 93.4 95.8 92.6 
Discordanta 17 vs 21 3 vs 3 3 vs 4 14 vs 17 
P-value b 0.63 1 1 0.72 
Aptima (N = 613) 
PreservCyt 476 (78) 100 0.98 0.30 
SurePath 446 (73) 0.99 0.93 0.35 
     
Agreement (%) 90.2 100 95.4 88.1 
Discordanta 45 vs 15 0 vs 0 8 vs 0 37 vs 15 
P-value b 1.3 x 10-4 1 0.01 0.003 
OncoHealth (N= 630) 
PreservCyt 356 (57) 0.58 0.60 0.45 
SurePath 301 (48) 0.55 0.52 0.54 
     
Agreement (%) 55.4 46.9 49.4 57.7 
Discordanta 168 vs 113 27 vs 24 51 vs 38 117 vs 75 
P-value b 0.001 0.78 0.203 0.003 
aPreservCyt+/SurePath- vs SurePath+/PreservCyt- 352 
b McNemar’s test  353 
c Number refers to the whole population of N=630. See Figure 1 for reduced numbers for HC2, 354 
PapType and Aptima  355 
356 
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Table 3.  359 
A) Median signal strength (viral load) by test, transport medium and order of the test for samples 360 
from women positive for at least one medium using the specified test. Units are the ratio to a 361 
reference sample except for RealTime and Onclarity which are CT values. Type specific results for 362 
HPV 16 and 18 (where available) are shown in the lower part of the table.  363 
B) 2-sided P-values for comparisons between different media and order using unpaired 364 
comparisons by the Wilcoxon RankSum test for samples positive for at least one medium. 365 
A) Median signal strength (RIU or CT) 366 
 Medium and order of sampling 
HPV Test PreservCyt 1st PreservCyt 2nd SurePath 1st SurePath 2nd 
HC2  235.03 292.80 90.54 53.08 
RealTime  21.30 22.03 23.64 25.85 
Onclarity 24.16 24.37 23.16 24. 32 
PapType 30.53 27.43 25.79 19.54 
Aptima 10.67 10.81 10.55 9.80 
OncoHealth 1.04 2.10 1.00 1.78 
RealTime 16 20.17 22.05 24.22 24.43 
RealTime 18 23.09 21.90 23.12 26.91 
Onclarity 16 25. 16 25.66 24.11 24. 75 
Onclarity 18 27.42 25.79 25.46 26.63 
PapType 16 28.43 32.28 27.83 19.88 
PapType 18 13.97 5.76 13.67 11.25 
B) Significance levels (2-sided) 367 
HPV Test PreservCyt 1st  
vs 
PreservCyt 2nd 
PreservCyt 1st  
vs 
SurePath 1st 
SurePath 1st 
vs 
SurePath 2nd 
PreservCyt 2nd  
vs 
SurePath 2nd 
HC2 0.998 0.009 0.011 1.04e-07 
RealTime 0.092 1.83 x 10-5 2.2 x 10-8 8.6 x 10-15 
Onclarity 0.104 0.033 0.011 0.182 
PapType   0.167 0.034 0.004 6.0 x 10-4 
 
Aptima 0.313 0.094 0.012 4.7 x 10-7 
 
OncoHealth 1.44 x 10-25 0.155 3.8 x 10-22 
 
1.2 x 10-4 
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RealTime 16 0.029 1.9 x 10-4 
 
0.038 2.0 x 10-5 
 
RealTime 18 0.859 0.414 0.024 0.004 
Onclarity 16 0.353 0.123 0.208 0.101 
Onclarity 18 0.781 0.174 0.314 1.000 
PapType 16 0.460 0.810 0.078 0.015 
PapType 18 0.857 0.754 0.512 0.967 
368 
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Table 4. Spearman's ρ Correlation coefficient and slope when SurePath values are regressed on 369 
PreservCyt values using L1 (robust) regression where values are either the log (1+RIU value) or 370 
(minus) Ct value and sample order is accounted for. (See methods section). One tailed p-values 371 
compare observed slope to unity (no difference in viral load between media).  372 
HPV Test N a Spearman’s ρ (95% CI) Slope (95%CI);            P-value  
                                     (vs unity) 
HC2 297 0.814 (0.771, 0.849) 0.966 (0.875, 1.057); p=0.231 
RealTime 481 0.724 (0.678, 0.764) 0.823 (0.724, 0.923); p=2.5 x 10-4 
Onclarity 499 0.884 (0.864, 0.902) 0.841 (0.778, 0.903); p=3.0 x 10-7 
PapType   486 0.756 (0.715, 0.792) 0.871 (0.780, 0.963); p= 0.003 
Aptima 491 0.683 (0.633, 0.727) 0.676 (0.514, 0.838); p=4.5 x 10-5  
OncoHealth 469 -0.133 (-0.221, -0.043) 0.242 (0.121, 0.362); p<2.010-16 
RealTime 16 159 0.574 (0.460, 0.670) 0.653 (0.400, 0.906); p= 0.004 
RealTime 18 55 0.660 (0.478, 0.787) 0.649 (0.242, 1.056); p=0.046 
Onclarity 16 161 0.838 (0.786, 0.879) 0.827 (0.677, 0.977); p= 0.012 
Onclarity 18 57 0.890 (0.820, 0.934) 0.833 (0.561, 1.105); p= 0.114 
PapType 16 166 0.771 (0.701, 0.826) 0.942 (0.839, 1.046); p=0.137 
PapType 18 88 0.748 (0.638, 0.828) 0.914 (0.735, 1.094); p=0.175 
a Positive at least for one test  373 
 374 
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Supplementary Table S1. Referral smear and worst reviewed histology  
Referral 
cytology (N) 
Worst histology (N) 
Normal 
colposcopy 
no biopsy 
Inade-
quate 
Normal 
CIN1/ 
HPV only 
CIN2 
CIN3 or 
CGIN 
Invasive 
carcinoma 
Total (% 
N) 
Borderline 
dyskaryosis 
No HPV triage 19 1 69 18 10 13 0 
130 
(20.6) 
Borderline 
dyskaryosis 
(HPV +ve) 5 1 27 17 10 3 0 
63 
(10.0) 
Mild 
dyskaryosis 
No HPV triage 52 5 134 67 48 32 0 
338 
(53.7) 
Mild 
dyskaryosis 
(HPV +ve) 4 0 12 16 4 6 0 
42  
(6.7) 
Moderate 
dyskaryosis 1 1 1 3 6 25 0 
37  
(5.9) 
Severe 
dyskaryosis/ 
glandular 0 0 0 1 2 15 2 
20  
(3.2) 
Total (%N) 
81 
(12.8) 
8 
(1.3) 
243 
(38.6) 
122 
(19.4) 
80 
(12.7) 
94 
(14.9) 
2 
(0.3) 
630 
(100.0) 
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Supplementary Figure S1. Sensitivity and Specificity for CIN3+ by HPV test and transport medium. 376 
Solid shapes show PreservCyt and open shapes are SurePath 377 
 378 
379 
26 
 
Supplementary Figure S2. Scatterplot of digene HPV Test RLU values for all tested samples. The 380 
solid line is the regression line for SurePath regressed on PreservCyt adjusted for sample order. 381 
The dashed line is the 45 degree line. Samples with PreservCyt first are open and those with 382 
SurePath first are solid. Shaded area indicates values below the positivity cut-off. 383 
 384 
 385 
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Supplementary Figure S3. Scatterplot of Realtime Ct values for samples that are amplified for at 387 
least one test. The solid line is the regression line for SurePath regressed on PreservCyt adjusted 388 
for sample order. The dashed line is the 45 degree line. Samples with PreservCyt first are open and 389 
those with SurePath first are solid. Shaded area indicates values below the positivity cut-off. 390 
 391 
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Supplementary Figure S4. Scatterplot of Onclarity Ct values for samples that are amplified for at 393 
least one test. The solid line is the regression line for SurePath regressed on PreservCyt adjusted 394 
for sample order. The dashed line is the 45 degree line. Samples with PreservCyt first are open and 395 
those with SurePath first are solid. Shaded area indicates values below the positivity cut-off. 396 
 397 
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Supplementary Figure S5. Scatterplot of PapType RIU values. The solid line is the regression line 399 
for SurePath regressed on PreservCyt adjusted for sample order. The dashed line is the 45 degree 400 
line. Samples with PreservCyt first are open and those with SurePath first are solid. Shaded area 401 
indicates values below the positivity cut-off. 402 
 403 
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Supplementary Figure S6. Scatterplot of Aptima RIU values. The solid line is the regression line for 405 
SurePath regressed on PreservCyt adjusted for sample order. The dashed line is the 45 degree line. 406 
Samples with PreservCyt first are open and those with SurePath first are solid. Shaded area 407 
indicates values below the positivity cut-off. 408 
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Supplementary Figure S7. Scatterplot of OncoHealth ROD values. The solid line is the regression 411 
line for SurePath regressed on PreservCyt adjusted for sample order. The dashed line is the 45 412 
degree line. Samples with PreservCyt first are open and those with SurePath first are solid. Shaded 413 
area indicates values below the positivity cut-off. 414 
 415 
 416 
